Detection of Enhanced In Vivo Platelet α-Granule Release in Different Patient Groups - Comparison of β-Thromboglobulin, Platelet Factor 4 and Thrombospondin Assays

Summary

During the platelet release reaction β-thromboglobulin (βTG), platelet factor 4 (PF4) and thrombospondin (TSP) are released from the platelet into plasma and assays of these proteins can be used to monitor in vivo platelet activation. We have assessed their relative merits as markers of the in vivo platelet α-granule release reaction in a number of patient groups which have previously been shown to have elevated plasma βTG and/or PF4 levels. It is concluded that in diseases or conditions not complicated by its reduced clearance, βTG is the most sensitive marker of in vivo platelet α-granule release. However, the TSP assay may be the least ambiguous when monitoring the platelet α-granule release reaction in patients with renal failure who are undergoing haemodialysis with heparin anticoagulation. Under these circumstances plasma βTG, but not PF4 or TSP, levels are elevated because of impaired renal catabolism, and the presence of a heparin-releasable reservoir of PF4 on the endothelium complicates the use of the PF4 assay. In liver failure none of these assays may accurately reflect platelet α-granule release because of impaired hepatic or renal elimination of the proteins.

Keywords

β-thromboglobulin - Platelet factor 4 - Thrombospondin

• References

• 1 Ludlam CA, Bolton AE, Moore S, Cash JD. A new method for diagnosis of deep venous thrombosis. Lancet 1975; 3: 259-260
• 2 Bolton AE, Ludlam CA, Pepper DS, Moore S, Cash JD. A radioimmunoassay for platelet factor 4. Thromb Res 1976; 8: 51-58
• 3 Weiss HJ, Witte L, Kaplan KL, Lager BA, Chemoff A, Nossel HL, Goodman DS, Baumgartner HR. Heterogeneity in storage pool deficiency: studies on granule-bound substances in 18 patients including variants deficient in α-granules, platelet factor 4, β-thromboglobulin, and platelet derived growth factor. Blood 1979; 54: 1296-1319
• 4 Smith RC, Duncanson J, Ruckley CV, Webber RG, Allan NC, Dawes J, Bolton AE, Hunter WM, Pepper DS, Cash JD. β-thromboglobulin and deep vein thrombosis. Thromb Haemostas 1978; 39: 338-345
• 5 Celia G, Zahavi J, DeHaas HA, Kakkar VV. β-thromboglobulin, platelet production time and platelet function in vascular disease. Br J Haematol 1979; 43: 127-136
• 6 White GC, Marouf AA. Platelet factor 4 levels in patients with coronary artery disease. J Lab Clin Med 1981; 97: 369-378
• 7 Celia G, Colby SI, Taylor AS, McCracken L, Parisi AF, Sasahara AA. Platelet factor 4 (PF4) and heparin-released platelet factor 4 (HR- PF4) in patients with cardiovascular disorders. Thromb Res 1983; 29: 499-509
• 8 Files JC, Malpass TW, Yee EK, Ritchie JL, Harker LA. Studies of human platelet α-granule release in vivo. Blood 1981; 58: 607-618
• 9 Turney JH, Williams LC, Fewell MR, Parsons V, Weston MJ. Platelet protection and heparin sparing with prostacyclin during regular dialysis therapy. Lancet 1980; 1: 219-222
• 10 Guzzo J, Niewiarowski S, Musial J, Bastl C, Grossman RA, Roa RK, Berman I, Paul D. Secreted platelet proteins with antiheparin and mitogenic activities in chronic renal failure. J Lab Clin Med 1980; 96: 102-113
• 11 Bastl CP, Musial J, Kloczewiak M, Guzzo J, Berman I, Niewiarowski S. Role of the kidney in the catabolic clearance of human platelet antiheparin proteins from rat circulation. Blood 1981; 57: 233-238
• 12 Dawes J, Smith RC, Pepper DS. The release, distribution and clearance of human β-thromboglobulin and platelet factor 4. Thromb Res 1978; 12: 851-861
• 13 Busch C, Dawes J, Pepper DS, Wateson A. Binding of platelet factor 4 to cultured human umbilical vein endothelial cells. Thromb Res 1980; 18: 128-131
• 14 Dawes J, Clemetson KJ, Gogstad GO, McGregor J, Clezardan P, Prowse PV, Pepper DS. A radioimmunoassay for thrombospondin, used in comparative study of thrombospondin, β-thrombospondin and platelet factor 4 in healthy volunteers. Thromb Res 1983; 29: 569-581
• 15 Ireland H, Lane DA, Wolff S, Foadi M. In vivo platelet release in myeloproliferative disorders. Thromb Haemostas 1982; 48: 41-45
• 16 Lane DA, Ireland H, Wolff S, Grant R, Jennings S, Allen-Mersh T. Plasma concentrations of fibrinopeptide A, fibrinogen fragment Bβ1- 42 and β-thromboglobulin following total hip replacement. Thromb Res 1982; 26: 111-118
• 17 Lane DA, Ireland H, Knight I, Wolff S, Kyle P, Curtis J. The significance of fibrinogen derivatives in plasma in human renal failure. Br J Haematol 1984; 56: 251-260
• 18 Ireland H, Lane DA, Curtis JR. Objective assessment of heparin requirements for haemodialysis in man. J Lab Clin Med 1984; 103: 643-652
• 19 Ludlam CA, Cash JD. Studies on the liberation of β-thromboglobulin from human platelets in vitro. Br J Haematol 1976; 33: 239-247
• 20 Rasi V. β-thromboglobulin in plasma: false high values caused by platelet enrichment of the top layer of plasma during centrifugation. Thromb Res 1979; 15: 543-547
• 21 Ludlam CA. Evidence for the platelet specificity of β-thromboglobulin on its plasma concentration in healthy individuals. Br J Haematol 1979; 41: 271-278
• 22 Kaplan KL, Owen J. Plasma levels of β-thromboglobulin and platelet factor 4 as indices of platelet activation in vivo. Blood 1981; 57: 199-202
• 23 Preston FE, Ward WD, Marcola BH, Porter NR, Timperley WR. Elevated β-thromboglobulin levels and circulating platelet aggregates in diabetic microangiopathy. Lancet 1978; 1: 238-240
• 24 Borsey DQ, Dawes J, Fraser DM, Prowse CV, Elton RA, Clark BF. Plasma β-thromboglobulin in diabetes mellitus. Diabetologia 1980; 138: 353-357
• 25 Bloom AL. Intravascular coagulation and the liver. Br J Haematol 1975; 30: 1-7
• 26 Phillips DR, Jennings LK, Pasasanna HR. Ca²⁺-mediated association of glycoprotein G (thrombin sensitive protein, thrombospondin) with human platelets. J Biol Chem 1980; 255: 11624-11632
• 27 Mosher DF, Doyle MJ, Jaffe EA. Synthesis and secretion of thrombospondin by cultured human endothelial cells. J Cell Biol 1982; 93: 343-348